Aspen Neuroscience Completes ASPIRO Cohorts 3 and 4 Dosing, Advancing Cryopreserved Sasineprocel Toward Phase 3

The shift from fresh to cryopreserved cell formulation in Aspen Neuroscience's ASPIRO trial is the manufacturing signal that process development and QA teams in autologous cell therapy should be tracking: it marks one of the first documented formulation transitions mid-program for an iPSC-derived therapy, with preclinical comparability data underpinning the change.

Aspen confirmed completion of dosing in Cohorts 3 and 4 of the ASPIRO Phase 1/2a trial of sasineprocel (ANPD001) as of June 30, 2026, bringing total patients dosed to 15. Cohorts 3 and 4 are the first to use the company's commercial-ready, cryopreserved thaw-and-inject formulation, replacing the fresh cell preparation used in Cohorts 1 and 2. The reformulated drug product is designed to arrive at the clinical site ready for immediate administration, removing dependence on on-site cell processing infrastructure and reducing procedural complexity at the point of care.

For manufacturing and regulatory leads, the comparability bridge between fresh and cryopreserved presentations is the operative compliance question. Aspen has characterized the cryopreserved formulation as preclinically comparable to earlier cohorts, a determination that will need to withstand ICH Q5C scrutiny and agency review as the program advances toward a Phase 3 IND package. How that comparability data is structured and documented will set a precedent for autologous iPSC programs navigating similar formulation transitions.

Clinical data from the earlier cohorts provides the efficacy context. At AD/PD 2026 in March, Aspen reported 12-month outcomes from the first eight patients across Cohorts 1 and 2: mean increases in Good ON time of 2.1 hours in the low-dose group (5 million cells per hemisphere) and 2.4 hours in the higher-dose group (5 to 10 million cells per hemisphere), alongside imaging evidence of graft survival and engraftment. No serious adverse events, severe graft-induced dyskinesia, hemorrhage, or immunosuppression requirements were reported across any participant. Six-month data published in 2025 had shown a 45% mean improvement in MDS-UPDRS Part III OFF scores and a 71% improvement in Part II scores in the first three patients.

Sasineprocel is manufactured from the patient's own skin biopsy, reprogrammed to iPSCs and differentiated into dopaminergic neuron precursor cells, then delivered bilaterally to the posterior putamen via MRI-guided surgery. The autologous origin eliminates the immunosuppression requirement that burdens allogeneic approaches, but it also means every batch is a single-patient manufacturing event, compressing the quality release timeline and placing acute pressure on comparability, stability, and logistics protocols at commercial scale.

The comparability package supporting the cryopreserved formulation, and its reception by regulators during Phase 3 alignment meetings, will be the measurable checkpoint that determines how quickly Aspen can advance to pivotal dosing.

Source: CGTLive via CGTLive.com, July 9, 2026.